Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
83.45
-0.69 (-0.82%)
At close: Dec 20, 2024, 4:00 PM
84.32
+0.87 (1.04%)
After-hours: Dec 20, 2024, 4:09 PM EST
Intra-Cellular Therapies Employees
Intra-Cellular Therapies had 610 employees as of December 31, 2023. The number of employees increased by 49 or 8.73% compared to the previous year.
Employees
610
Change (1Y)
49
Growth (1Y)
8.73%
Revenue / Employee
$1,006,111
Profits / Employee
-$141,590
Market Cap
8.85B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 610 | 49 | 8.73% |
Dec 31, 2022 | 561 | 49 | 9.57% |
Dec 31, 2021 | 512 | 129 | 33.68% |
Dec 31, 2020 | 383 | 53 | 16.06% |
Dec 31, 2019 | 330 | 257 | 352.05% |
Dec 31, 2018 | 73 | 24 | 48.98% |
Dec 31, 2017 | 49 | 7 | 16.67% |
Dec 31, 2016 | 42 | 3 | 7.69% |
Dec 31, 2015 | 39 | 13 | 50.00% |
Dec 31, 2014 | 26 | 4 | 18.18% |
Mar 31, 2013 | 22 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Henry Schein | 25,000 |
Bruker | 9,707 |
Bio-Rad Laboratories | 8,030 |
Bio-Rad Laboratories | 8,030 |
Penumbra | 4,200 |
Masimo | 3,800 |
Repligen | 1,783 |
Exelixis | 1,310 |
ITCI News
- 10 days ago - Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting - GlobeNewsWire
- 13 days ago - Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move - Seeking Alpha
- 18 days ago - Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy - GlobeNewsWire
- 4 weeks ago - Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress - GlobeNewsWire
- 6 weeks ago - Intra-Cellular's schizophrenia drug meets main goal in late-stage trial - Reuters
- 7 weeks ago - Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance - GlobeNewsWire